Marshall Wace, LLP Immuneering Corp Transaction History
Marshall Wace, LLP
- $78.4 Billion
- Q4 2024
A detailed history of Marshall Wace, LLP transactions in Immuneering Corp stock. As of the latest transaction made, Marshall Wace, LLP holds 21,432 shares of IMRX stock, worth $40,292. This represents 0.0% of its overall portfolio holdings.
Number of Shares
21,432Holding current value
$40,292% of portfolio
0.0%Shares
5 transactions
Others Institutions Holding IMRX
# of Institutions
42Shares Held
4.68MCall Options Held
0Put Options Held
0-
Vanguard Group Inc Valley Forge, PA1.06MShares$1.99 Million0.0% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD767KShares$1.44 Million0.0% of portfolio
-
Black Rock Inc. New York, NY533KShares$1 Million0.0% of portfolio
-
Morgan Stanley New York, NY454KShares$853,7080.0% of portfolio
-
Southport Management, L.L.C. Wilson, WY215KShares$404,2001.71% of portfolio
About Immuneering Corp
- Ticker IMRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,392,300
- Market Cap $49.6M
- Description
- Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to tr...